On Monday, Hikma announced a partnership with Celltrion to market YUFLYMA (CT-P17) in the Middle East and North Africa. CT-P17 is a high-concentration, low-volume and citrate-free adalimumab biosimilar, indicated for the treatment of a number of conditions including rheumatoid arthritis, ankylosing spondylitis, and Crohn’s disease. According to Hikma, CT-P17 provides pain-reducing features and causes less pain upon injection. The partnership agreement would give Hikma exclusive rights to commercialize YUFLYMA in all of its Middle East/North Africa markets.
![](https://www.bigmoleculewatch.com/wp-content/uploads/sites/2/2022/02/250x170-Deal-Watch.jpg)